MedTrace Logo

Tumor-Infiltrating Lymphocytes in Endometrial Cancer

NCT06976333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2025-05-16

No results posted yet for this study

Summary

Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components. Among these proteins, CD133, WNT-1, and mTOR have emerged as key molecular markers with potential prognostic and therapeutic implications in EC. Understanding the association between these molecular alterations and the immune contexture of EC can provide valuable insights into EC biology and lead to the identification of novel therapeutic targets.

In this study, the spatial organization of tumor-infiltrating lymphocytes (TILs) in EC and their correlations with tumor grade, stage, and subcellular CD133, WNT-1, and mTOR expression were investigated. Artificial intelligence-assisted image analysis was performed to quantify TIL metrics, including TIL percentage, grey level co-occurrence matrix (GLCM M1 and M2) parameters, and fractal dimension (FD).

Conditions

  • Endometrium Cancer
  • Tumor Infiltration

Interventions

DIAGNOSTIC_TEST

Tumor-infliltrating lymphocyte (TIL) percentage

TIL percentage was calculated as the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]

DIAGNOSTIC_TEST

Grey level co-occurrence matrix (GLCM)

The GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterized more structured images with distinct TIL patterns.

DIAGNOSTIC_TEST

Fractal dimension (FD)

Quantification of the complexity of TIL

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Milosz Pietrus, PhD · Jagiellonian University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-04-30
Completion
2025-05-08

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06976333 on ClinicalTrials.gov